InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: geocappy1 post# 191246

Sunday, 09/21/2014 11:22:10 AM

Sunday, September 21, 2014 11:22:10 AM

Post# of 345756

Biopharm and his math errors.



error(s) ?? lol

-----------------------------------------

Geo, my quote below is what you have been harping over and seeming to cause lots of confusion. My 15 year old figured out in 12 seconds I meant to say $2.5 Million (as in investment) vs 2.5 Million shares. Maybe it was confusing because I skipped the step that shows how I came up with $2.5 Million, which is 100,000 preferred shares * $25 = $2.5 Million.

1) Lets say we sign a deal with the very top collaborator that holds the most promise and they buy into Peregrine, lets say a stake like 100k preferred shares = about 2.5 Million shares just using 8x as the multiplier.



This all started, because I was trying to figure out "if" its possible if PS Targeting is used for all treatment, "HOW" Peregrine structures those initial collaborations and was thinking more so of maybe selling preferred shares in 100,000 lots, which would turn out to be $2.5 Million to join the Bavi club. So $2.5 Million just to mix downstream drugs with the "constant" of PS Targeting...

Of course.... they can structure it further where one must pay yearly fees to continue testing their drugs with PS Targeting and for those that receive FDA approvals, further pay a fee on acceptance based on some algo numbers and royalties..etc.




"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News